In a major advancement for cancer care, the NHS has approved a new combination treatment for primary advanced or recurrent endometrial cancer, marking the first time immunotherapy has been used alongside chemotherapy as a first-line option for this patient group.
The treatment combines pembrolizumab (Keytruda), an immunotherapy developed by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab helps the immune system recognise and attack cancer cells, while chemotherapy works to stop their growth and division.
Clinical trials show that this dual approach reduces the risk of death by 26% compared to chemotherapy alone and slows cancer progression, offering patients valuable additional time and improved quality of life.
The treatment is available immediately via the Cancer Drugs Fund, following a commercial agreement that ensures cost-effectiveness and rapid access for eligible patients. Around 2,100 patients are expected to benefit each year.
Helen Knight, NICE’s Director of Medicines Evaluation, said:
"For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option. It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer."
Treatment can continue for up to two years, or be stopped earlier depending on individual response or side effects, allowing for personalised care.
Endometrial cancer is the most common gynaecological cancer in the UK, with approximately 9,700 diagnoses annually. For those diagnosed at stage 4, only 15% survive beyond five years, highlighting the urgent need for more effective treatments.
Image credit: iStock
